Drug Trial Radar · NCT05216835
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Mar 18, 2022
Primary completion
Aug 30, 2024
Study completion Sep 4, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Feb 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 101 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
Conditions
- Relapsed or Refractory Classical Hodgkin Lymphoma
Interventions
Sabestomig (AZD7789)Drug
Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A (Dose Escalation): Number of Participants With Adverse Events (AEs)Time frame: From start of treatment [Cycle 1 Day 1 (C1D1) (each cycle was 28 days)] up to 90 days post last dose (approximately 2 years 5 months)
- Part A (Dose Escalation): Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: From first dose (C1D1) until 28 days for each participant [within 28 days DLT period]
- Part B (Dose Expansion): Cohort B1: Objective Response Rate (ORR)Time frame: Up to approximately 2 years 90 days
- Part B (Dose Expansion): Cohort B2: Complete Response Rate (CRR)Time frame: Up to approximately 2 years 90 days
- Part B (Dose Expansion): Number of Participants With AEsTime frame: Up to approximately 2 years 90 days
Locations
14 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
Miami, Florida
Research Site
Rochester, Minnesota
Research Site
New York, New York
Research Site
Houston, Texas
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
København Ø, Denmark
Research Site
Lille, France
Research Site
Bologna, Italy
Research Site
Naples, Italy
Research Site
Valencia, Spain
Research Site
Manchester, United Kingdom
Research Site
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.